# FY2024 (Ended February 28, 2025) Financial Briefing



Apr 11, 2025
RORZE CORPORATION

(Code: 6323)

https://www.rorze.com/ir

#### Disclaimer

#### Regarding forward-looking statements

The business forecasts and other forward-looking statements contained in this document are based on judgments made in accordance with information currently available for our company and do not constitute a guarantee or promise of the accuracy or completeness of such information. The forecast is also subject to change without notice due to changes in economic conditions, industry competition, markets and other systems.

#### Data included in this document are stated as follows

JPY values : Rounded down to the nearest unit

Percentages : Rounded to the nearest unit after calculated in units of 1 JPY

Fiscal year : Refer to the "fiscal year ended February 28, 2025" as "FY2024" or "FY'24,"

Accounting period: The accounting periods of the consolidated, head office, and domestic and overseas subsidiaries are as follows:

	Q1 (1st Quarter)	Q2 (2nd Quarter)	Q3 (3rd Quarter)	Q4 (4th Quarter)	Full-year
Consolidated/RORZE/Domestic subsidiaries	Mar.∼May.	Jun.∼Aug.	Sep.∼Nov.	Dec.∼ The following Feb.	Mar.∼ The following Feb.
Overseas subsidiaries	Jan.∼Mar.	Apr.~Jun.	Jul.∼Sep.	Oct.~Dec.	Jan.∼Dec.

### Company Profile

Name RORZE CORPORATION

Listed Market

Tokyo Stock Exchange Prime Market

(Securities code: 6323)

**Head Office** 1588-2 Michinoue Kannabe-cho, Fukuyama-shi, Hiroshima

Establishment March 30, 1985

Capital 982 million JPY

**Business** Development, design, manufacturing, and sales of automation system for

semiconductor/FPD production and life science automation products

Employees Consolidated : 4,402 Non-consolidated : 244


(As of February 28, 2025)

**Locations** Japan: Fukuyama · Yokohama · Kumamoto · Tsukuba · Tokyo

Overseas: USA / Vietnam / Taiwan / Korea / Singapore/ China /

Germany

#### Number of employees (consolidated)



#### Global Network



- R&D, Manufacturing, Sales, Support
- Sales, Support
- R&D, Manufacturing
- Support






FY2024 (March 1, 2024~February 28, 2025) Consolidated Business Results

### Summary of FY2024

for the period

Strong sales of Semi and FPD drove revenue to 124.4 billion JPY, ordinary profit increase by enhanced mass production and weakened JPY



\* From FY2024, "motor control equipment" is included in "Service/Parts etc.".



#### FY2024 Consolidated business result

	FY'24 result	FY'24 Plan	Achievement (%)	FY'23 result	YoY(%)
Net sales	124,406	120,784	103.0	93,247	133.4
Semi	102,368	102,399	100.0	78,946	129.7
Analysis device	3,425	3,841	89.2	3,112	110.0
FPD	8,593	6,511	132.0	3,713	231.4
Life science	1,074	1,300	82.6	1,220	88.1
	8,943	6,732	132.8	6,254	143.0
Operating Profit	32,024	31,617	101.3	24,138	132.7
Ordinary Profit	35,454	31,518	112.5	27,076	130.9
Profit attributable to owners of parent	23,634	22,916	103.1	19,576	120.7

#### Net sales (Semi) 102.3 billion JPY (30% up YoY)

Growing demand for generative AI has accelerated the capital investment in advanced semiconductors

- Sales to key equipment manufacturers in USA grew YoY
- Equipment shipments to Taiwanese foundries have been strong

# ■ Net sales (FPD) 8.5 billion JPY (131% up YoY)


- Shipment of the large substrate transfer system ordered by a Korean customer led the FPD equipment sales
- Ordinary profit increased by weaker JPY



<sup>\*</sup> From FY2024, "motor control equipment" is included in "Service/Parts etc.".


### Net sales by regions

Sales to US, Taiwan, Japan and Korea (in FPD) increased while sales to China decreased



### Factors behind the change in operating profit

 Increased Sales of Semi and FPD ensured operating profit growth, while labor costs and goodwill amortization had an impact on it



※ The impact of Nanoverse on consolidated operating profit: ▲3,059 million JPY (Goodwill amortization amount 1,425 million JPY, Operating loss: 1,633 million JPY)

### Trends in orders, sales, and backlog

52,180

FY'24

# Semiconductor related equipment


FY'23

(Million JPY) 56,399

- Sales amount increased with sales growth in advanced semiconductors for Taiwan and USA while sales to China decreased
- Order amount for some memory manufactures and advanced package related items increased while that for Chinese customers decreased

52,464

FY'24



53,467

FY'24


FY'24

52,834

### Trends in orders, sales, and backlog

#### Analysis equipment


- The sales amount recovered, driven by sales growth to device manufacturers and the research institutions in Europe and Japan
- The order amount increased mainly from wafer manufacture



### Trends in orders, sales, and backlog


#### FPD


- Sales amount significantly increased by the installation of large substrate transfer system ordered in Q3
- · New orders for another substrate transfer system equipment were placed in Q4




#### Consolidated balance sheet

 High level cash and deposits from increased profits enable large-scale capital investment covered by internal fund





### FY2024 Consolidated cash flows





FY2025 Business Forecast

#### Future outlook and forecast for FY2025

#### [Market environment]

- From economic security perspective, while USA has tightened export controls to China, government support for domestic semiconductor production has continued globally and supply chain has been geopolitically fragmented
- Impact of U.S. tariff measures
- Expansion of demand for advanced highperformance semiconductors driven by growing Al technology and data processing need
- Acceleration of semiconductor capital investment in advanced packaging for higher density integration and expanded function

#### [Future outlook]

#### ■ Semi

- Increase in equipment shipment for the advanced devices responding to the strong capital investment by Taiwanese foundries
- Stable demand in EFEM for USA and China and equipment for memory makers
- Analysis device
  - implementation for sales and service functions within RORZE group and increasing new product orders

#### ■ FPD

- · Recoil reduction after large equipment installation
- Life science
  - Enhancement in new product development and full year contribution of Genostaff




### FY2025 Consolidated business forecast

	FY2025 Forecast (Million JPY)	FY2024 Result (Million JPY)	YoY (%)
Net sales	128,190	124,406	103.0
Semi	106,893	102,368	104.4
Analysis device %2	4,163	3,946	105.5
FPD	6,550	8,593	76.2 <sup>80</sup>
Life science	1,590	1,074	148.0
Service/Parts etc. %2	8,992	8,423	106.8
Operating profit	30,345	32,024	94.8
Ordinary profit	30,618	35,454	86.4
Profit attributable to owners of parent	23,499	23,634	99.4 20.1
Exchange rate(JPY/USD)※1	152	151	_

X1 Starting from FY2024, performance forecasts and actual results are based on the average rate for the period.

X2 Starting from FY2025, the scope of sales by product has been revised. In the table above, the figures for FY2024 have been recalculated to be comparable, so the values for "Analysis device" and "Service/Parts etc." differ from those in our previous pages.






### Capital investment / Depreciation / R&D

#### ◆ Capital investment / Depreciation

- Installation of machinery required for the automated assembly line and renewal of processing machinery at the current factory in Vietnam
- Funding for land acquisition for the new factory in Vietnam
   Land acquisition is expected in 2026 because of delays from
   government reorganization, with construction starting the same
   year and the first phase completed the following year
- Headquarter expansion to accommodate employee growth
- Expansion of the clean room at the USA office site
- Depreciation is expected to be 3.3 billion JPY

#### ◆ R&D

- New products in vacuum wafer handling system
- · Equipment for advanced packaging line
- Developing foundational technologies for next-generation products







Topics

### Supplementary Information

#### ■ Extraordinary loss (loss on devaluation of investment securities)

The affiliated company Shanghai ReMed Biotechnology Co., Ltd., working with the RORZE's Life Science field specifically in the regenerative medicine in China, has implemented the clinical trials and the introduction of automated cell culture equipment with recording profit in 2024. However, at major medical institutions in China, the impact of the confusion caused by the coronavirus measure and the subsequent purge against corruption is so significant for cutting-edge medical treatment that the need for cell culture can not grow strongly as expected earlier. It was concluded that it would be difficult to achieve the business plan premised on high market growth in the early stages. As a result, a loss of 2.1 billion JPY was recorded on the company's shares in FY2024.

#### ■ The impact for consolidated business results by Nanoverse Technologies, Ltd("NV")

	FY2024 Result	FY2025 Forecast
Impact on Operating Income	$\triangle$ 3.0 billion JPY	$\triangle$ 6.0 billion JPY
(Goodwill Amortization)	(1.4)	(2.8)
(NV's Operating Loss)	(1.6)	(3.2)
Impact on Profit attributable to owners of parent *	△2.0	△3.8

\*The amount of impact on Profit attributable to owners of parent is roughly sum of the equivalent amount to 33% (RORZE's shareholding ratio) of NV's operating loss and the amount of amortization of goodwill

Furthermore, the timing of sales recognition for the equipment under development is expected to be in or after the fiscal year ending February 2027



#### RORZE IAS

#### Company Name Change

IAS Inc, (CEO Katsuhiko Kawabata, HQ Hino city in Tokyo), having joined in RORZE group in March, 2023, changed its name as RORZE IAS Inc, on March 1, 2025

[New Company Name] RORZE IAS Inc.



[New web site] https://rorze-ias.com/

(Reference) Results of the two-year management integration; Incorporated sales and service operations for major customers into the group and replaced the wafer handling mechanisms in its analysis device by RORZE products.




The new product "LAGM/Expert LA" (analysis device) is highly evaluated for its new technology-based wafer contaminant detection function and has been introduced to Leading-edge Semiconductor Technology Center(LSTC)

#### Return to shareholders

#### Return to shareholders

Recognizing the return of profits to shareholders as one of the most important management issues, our policy is to return profits based on a comprehensive consideration of factors such as business performance and financial position, while maintaining stable dividends and securing the internal reserves necessary for future business development and strengthening of the management structure.

#### ■ Dividend per share (year-end dividend)



<sup>\*\*</sup>On September 1, 2024, RORZE carried out a 10-for-1 stock split for its common shares. For this reason, the dividend per share amount takes into account the impact of this stock split.

<sup>\*\*</sup>The dividend per share for the fiscal year ending February 2025 is planned to be 17 JPY, an increase of 1 JPY from the initial plan of 16 JPY.



### Acquisition of Treasury Shares

\*This page is exactly same as "Notice of Resolution on Acquisition of Treasury Shares" released on April 11,2025

Class of shares	Common shares
Total number of shares that can be acquired	5,300,000 shares (3.0% of total number of issued shares (excluding treasury shares))
Total amount of share acquisition costs	maximum of 5,000 million JPY
Acquisition period	From April 14, 2025 to July 31, 2025
Acquisition Method	Market purchase on the Tokyo Stock Exchange

(Reference) Total number of shares outstanding and number of treasury shares as of February 28, 2025


- Total number of issued shares (excluding treasury shares) 176,365,140 shares
- Number of treasury shares 34,860 shares





References

### Semi



N2 Purge Wafer Stocker

Equipment

manufacturers(SPE)

Process equipment

Inspection equipment

End -user

Device manufacturers


Wafer manufacturers



### Advanced packaging line

#### Advanced packaging

Method for connecting chiplet to achieve higher device density and functionality expansion with a smaller footprint



## Advanced packaging line



PLP EFEM





Tape Frame Sorter



### Analysis device





Semiconductor industry

**SPEs** 

End-user
Device
manufacturers
Wafer manufacturers


#### Other industry

Research institution
Environmental measuring
Instrument manufacturer
Chemical manufacturer etc.



### **FPD**










Front-end:

FPD manufacturers
Glass for FPD
manufacturers







Back-end:
FPD manufacturers



### Life science





Incubator SCALE48



CO<sub>2</sub> Incubator with medium exchange function & cell imaging function CellKeeper® II 48Plus




Mobile robot



Automatic medium exchange system CellFarm(L)-360™



Scheduling software Green Button Go<sup>TM</sup> ※ (\*\*Product of Biosero)







# Thank you